Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. (NASDAQ: COSM) generates a steady flow of news across pharmaceuticals, nutraceuticals, healthcare services and digital assets, reflecting its description as a diversified, vertically integrated global healthcare group. News coverage often highlights developments in its proprietary brands, EU-based manufacturing operations, distribution activities, research and development programs, telehealth initiatives and financing arrangements.
Recent press releases have focused on record quarterly financial results, including revenue growth and margin expansion attributed to contract manufacturing at Cana Laboratories, UK distribution through Decahedron, the CosmoFarm distribution business, and global expansion of brands such as Sky Premium Life and C-Sept/C-Scrub. Coverage has also included manufacturing agreements, such as the PathMuscle production agreement through Cana Laboratories, which illustrates the company’s role as a pharmaceutical manufacturing partner.
Investors following COSM news will also see updates on Cosmos Health’s R&D pipeline, including programs like CCX0722 for obesity and weight management and other repurposed compounds targeting major disorders. News items describe how these efforts are supported by the Cloudscreen AI-enabled drug repurposing platform and by initiatives in nanotechnology to develop next-generation nutraceutical formulas.
Beyond core healthcare operations, Cosmos Health issues news about its digital asset strategy, including Ethereum purchases under a $300 million facility and a strategic partnership with Prime Ledger LLC to manage digital asset treasury operations and tokenize intellectual property. Regulatory and capital markets updates, such as Nasdaq listing compliance notices, financing transactions involving senior secured convertible notes, and shareholder meeting outcomes, also feature prominently.
For readers tracking COSM, this news stream provides insight into how the company is executing across manufacturing, distribution, R&D, telehealth and digital finance. Regular updates help contextualize financial performance, strategic partnerships and regulatory milestones that shape Cosmos Health’s trajectory.
Cosmos Health (NASDAQ:COSM) launched the 18 Series in the U.S. on April 21, 2026: a science-first nutraceutical platform requiring a patented ingredient, peer-reviewed clinical evidence, and the exact clinical dose.
Three products—Noor18, Liv18, Cur18—target a combined $7.8B U.S. addressable market, cite published RCTs (7+ studies), and use patented actives to build a compounding portfolio aiming for 18 clinically validated products.
Cosmos Health (NASDAQ:COSM) completed Phase 1 for Liv18, finalizing product development, packaging, and initial commercial setup ahead of schedule. U.S. production begins April 2026 at GMP-certified, FDA-registered, UL-audited facilities to reduce tariff exposure and improve supply chain efficiency.
The company projects over $5M in annual revenue for Liv18 at approximately 75% gross margins, driven by a direct-to-consumer model and targeted advertising; early U.S. traction from other products informs commercial expectations.
Cosmos Health (NASDAQ:COSM) will launch Cur18 in the U.S. in Q2 2026, a patented, turmeric‑derived curcumin supplement standardized to ~50% curcuminoids and derived ~98.5% from turmeric.
Published pharmacokinetic research reports up to 39× higher free curcumin bioavailability and 49.5× higher AUC versus standard 95% extracts.
Cosmos Health (NASDAQ:COSM) announced expanded integration of artificial intelligence across operations on April 16, 2026, targeting efficiency, cost reduction, improved customer experience, and sales growth. In certain areas, AI may reduce specific operating expenses by up to 30%, depending on process and automation level.
The company is deploying AI across front-end order and customer management, back-end warehouse, inventory and supply chain, and its proprietary Cloudscreen platform for drug repurposing, supporting both operational gains and R&D efforts.
Cosmos Health (NASDAQ:COSM) reported record FY 2025 revenue of $65.27M, up 20% year-over-year, with gross profit of $7.90M (up 83%) and gross margin expanding 418 basis points to 12.10%. Cash rose to $3.46M and total assets to $65.48M; net loss was $19.14M.
The company highlighted contract manufacturing agreements for over 12 million units, 300,000+ Sky Premium Life purchase orders, a $300M financing facility for a digital asset treasury, and continued 2026 momentum across core segments.
Cosmos Health (NASDAQ:COSM) received a third consecutive purchase order from Pharmalink for 60,000 units of Sky Premium Life in the UAE, taking cumulative orders to 270,000 units since June 2024.
The order follows prior purchases of 130,000 and 80,000 units and advances Cosmos toward a 3 million‑unit five‑year partnership goal with Pharmalink.
Cosmos Health (NASDAQ:COSM) reported no material operational impact from the Iran and Middle East conflict and said record revenue momentum continues. Q3 2025 revenue reached $17.1M (+38% YoY); gross profit $2.6M (+116%) with a 15.21% margin; cash rose to $4.63M from $0.66M.
The company said U.S. rollout of NOOR collagen is on track, produced in GMP/FDA-registered facilities, and projected to exceed $12M revenue within 12 months with ~75% gross margins.
Cosmos Health (NASDAQ:COSM) will launch Liv18™ in the U.S. in Q2 2026, a 600 mg/day liver health supplement powered by patented BergacynFF®, supported by two randomized, double‑blind, placebo‑controlled trials showing 9–15% liver fat reduction versus placebo.
Products are manufactured in GMP, FDA‑registered U.S. facilities and target the $4.6B U.S. liver supplements market.
Cosmos Health (NASDAQ:COSM) announced that C-Scrub Wash 4%, made by subsidiary Cana Laboratories, successfully completed testing under EN 12791:2016+A1:2017, the European surgical hand disinfection standard. The independent QACS study confirmed effective antimicrobial activity for surgical hand antisepsis.
The company says this supports expansion into hospital, surgical, and institutional healthcare channels, strengthens the C-Scrub brand, and complements growing commercial availability in the United Kingdom.
Cosmos Health (NASDAQ:COSM) reports record revenue, improving operating metrics, and significant U.S. expansion with locally manufactured Sky Premium Life products. Management projects ~75% gross margins for U.S. operations and expects NOOR Collagen to generate >$12M annualized revenue.
The company entered an LOI to buy an $11.5M pharmacy distribution network, holds >$18M in non-core assets, and will issue updated guidance after FY2025 results.